Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02414139 · ClinicalTrials.gov registry record · Phase 2

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
373
Enrollment target
20
Study locations

NCT02414139: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Novartis Pharmaceuticals.

NCT02414139 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 373 participants, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02414139, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
373 participants
Enrollment target
20
Study locations

Study Summary

Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK)-negative rearrangement, and mesenchymal epithelial transition (MET) mutations leading to exon 14 deletion (referred to as MET mutation hereafter) and/or MET amplification.

Primary Outcome

Percentage of participants with a best overall response defined as confirmed complete response (CR) or partial response (PR) by BIRC assessment per RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Capmatinib

Study Locations (20)

California

  • Pacific Shores Medical Group SC - Long Beach
  • University Of California Los Angeles Dept of Onc - Los Angeles
  • University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center - Orange

Other

  • Novartis Investigative Site - La Rioja
  • Novartis Investigative Site - Vienna
  • Novartis Investigative Site - Leuven

Pennsylvania

  • Lehigh Valley Health Network SC - Allentown
  • Andrew and Patel Associates - Camp Hill

Florida

  • H Lee Moffitt Cancer Center and Research Institute . - Tampa

Iowa

  • University of Iowa Hospitals and Clinics SC-3 - Iowa City

Massachusetts

  • Massachusetts General Hospital MGH Cancer Center - Boston

Michigan

  • VA Ann Arbor Health System VA Ann Arbor Health System - Ann Arbor

Minnesota

  • Mayo Clinic Rochester . - Rochester

Trial Details

FieldValue
Enrollment Target 373 participants
Start Date 2015-06-11
Est. Completion 2023-05-16
Phase Phase 2
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT02414139 record still lists

NCT02414139 is an interventional study that assigns participants to a tested intervention. The registered 373 participants enrollment target is mid-sized for trials with a published cap, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (16% higher).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Capmatinib is the first listed.

NCT02414139 names 20 study sites across 15 states, led by California, Other, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02414139 about?

NCT02414139 is a clinical study titled "Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)". Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations...

What is the current status of trial NCT02414139?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 373 participants. The study started on 2015-06-11. Estimated completion is 2023-05-16.

What conditions does trial NCT02414139 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT02414139?

The interventions under investigation include: Capmatinib (DRUG).

Who is sponsoring clinical trial NCT02414139?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02414139 being conducted?

This trial has 20 study locations across California, Florida, Iowa, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02414139's enrollment target sits among peer trials

373 35th of 130 higher than 96 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07276750 · 373 participants · NA

    Coaching and Leadership in Autism Support Settings

  • NCT04801589 · 372 participants · Phase 3

    Goal-Directed Sedation in Mechanically Ventilated Infants and Children

  • NCT04879329 · 372 participants · Phase 2

    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • NCT05318105 · 372 participants · NA

    Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02414139, the US trial registry maintained by the National Library of Medicine. NCT02414139 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.